Clinical Trial Update: An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing two concentrations of PDI-192 (0.1% vs 0.15%) for mild-to-moderate atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• PDI-192 (PDI-192)

Snippet

Sponsor: PreCision Dermatology, Inc. | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED